Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Elongation of very long-chain fatty acid protein 1 (ELOVL1)
- Target
- ELOVL1
- Molecular classification
- Enzyme, Fatty acid elongase, Endoplasmic reticulum membrane protein
01
Overview
Elongation of very long-chain fatty acid protein 1 (ELOVL1) is an integral membrane enzyme of the endoplasmic reticulum that catalyzes the first and rate-limiting step in the elongation of long- and very long-chain saturated and monounsaturated fatty acids, primarily targeting C22:0 acyl-CoA substrates. This process is essential for the biosynthesis of membrane lipids and sphingolipids, which are crucial in the central nervous system, skin, and other organs. Mutations in ELOVL1 are linked to rare genetic disorders involving ichthyosis, spasticity, hypomyelination, and other neurological symptoms[1][2][8]. No approved drugs currently target ELOVL1 directly, but it is considered a potential therapeutic target due to its role in lipid metabolism and associated diseases[2].
- Other names
- ELOVL fatty acid elongase 1Elongation of very long chain fatty acids protein 1ELOVL1
02
Mechanism of action
Inhibition of fatty acid elongase activity (theoretical); Modulation of VLCFA synthesis (theoretical)
03
Biological functions
Fatty acid biosynthetic processSphingolipid biosynthetic processElongation of very long-chain fatty acids (VLCFAs)
04
Disease associations
Skin disorder (Ichthyotic keratoderma)Neurological disorder (Spasticity, Hypomyelination, Spinocerebellar ataxia)Other (Dysmorphic facial features)
05
Safety considerations
VLCFA accumulation causing toxicityPotential effects on skin barrier and myelin integrity
06
Biomarkers
VLCFA plasma/tissue levels (used in peroxisomal and some neurocutaneous disorders)Genetic mutation in ELOVL1 (for certain inherited diseases)
Beyond the preview
Go deeper on Elongation of very long-chain fatty acid protein 1 (ELOVL1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Elongation of very long-chain fatty acid protein 1 (ELOVL1).